Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

3SBio Files China IND for Anti-Autoimmune mAb from Apexigen

publication date: Aug 17, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio filed an Investigational New Drug (IND) application with the SFDA to begin clinical trials of a monoclonal antibody drug candidate discovered by Apexigen of San Francisco. SSS07, also known as APX001, will be tested as a treatment for autoimmune and inflammatory diseases. 3SBio completed the development work on the China filing and owns China rights to the molecule. More details....

Stock Symbol: (NSDQ: SSRX)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
ChinaBio® Events
CBPF2016
Suzhou, China
May 18 - 19, 2016
Record attendance of 1008!
See us next year in Shunde!

>> More events...

Other Events
Hong Kong, China
June 15–17, 2016
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors